Taurolidine/Heparin sodium/Sodium Citrate

牛磺罗定/肝素钠/枸橼酸钠

Report date: 2024/04/28 18:34:38
NMEQIDP

Base Information

Drug NameTaurolidine/Heparin sodium/Sodium Citrate
Drug Alias NameCitrate/heparin/taurolidineCitrate/taurolidine/heparinHeparin/citrate/taurolidineHeparin/taurolidine/citrateTaurolidine/citrate/heparin +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLipopolysaccharide (LPS) inhibitorsAntithrombin-III activators
TargetsLipopolysaccharide (LPS)Antithrombin-III
Therapy Area/IndicationsVein diseaseInfections
Global Approved IndicationsInfections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/11/15
Country/TerritoryUnited States
CombinationsYes TaurolidineHeparin sodiumSodium Citrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesND Partners LLC
China Registration ClassN/A

Develop Information

Active CompaniesCormedix Inc
Inactive CompaniesN/A
Active IndicationsVein diseaseInfections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A